Monday, December 5, 2016

BRIEF-Celyad announces positive new data from its CAR-T NKR-2 Phase I Trial

* Cases of prolonged survival with improvements in hematological parameters were noted in

both acute myeloid leukemia (AML) and multiple myeloma (MM) patients

Read more
Posted by at

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)